新型利福霉素对革兰氏阳性临床分离株的体外活性
In vitro activity of novel rifamycins against gram-positive clinical isolates.
作者信息
Murphy Christopher K, Karginova Elena, Sahm Dan, Rothstein David M
机构信息
ActivBiotics, Inc., Lexington, MA 02421, USA.
出版信息
J Antibiot (Tokyo). 2007 Sep;60(9):572-6. doi: 10.1038/ja.2007.72.
PMID:17917240
Abstract
We describe novel rifamycins that have improved activity, compared with rifampin, against clinical isolates of staphylococci and streptococci, with MIC(90)s of 0.008 and 0.0005 microg/ml, respectively. This enhanced antibacterial activity, along with their potential lack of drug-drug interactions, are considerations that suggest the potential of these novel rifamycins in combination therapy to treat serious Gram-positive infections.
摘要
我们描述了新型利福霉素，与利福平相比，它们对葡萄球菌和链球菌临床分离株具有更高的活性，其MIC(90)分别为0.008和0.0005微克/毫升。这种增强的抗菌活性，以及它们可能不存在药物相互作用，提示了这些新型利福霉素在联合治疗严重革兰氏阳性菌感染方面的潜力。
Zotero 插件